Nutritional state has profound actions at all levels of the GHaIGF-I axis and growth hormone has potent effects on nutritional state. The growth promoting effects of GH on linear height in children has long been recognised and, more recently, the important action of GH in maintaining adult body composition have been appreciated. The strong anabolic actions of GH have made it a drug of abuse among athletes and, of interest, clinicians, as a potent anticatabolic therapy. In this review we consider the effects of nutrition on the GHaIGF-I axis and then discuss its potential use as an anti-catabolic agent. We also note the recent study in critically ill patients which has been associated with a poor outcome using high dose GH therapy.
Introduction
Growth hormone (GH) is secreted in a pulsatile fashion from the anterior pituitary under the dynamic control of at least two hypothalamic peptides including growth hormone releasing hormone (GHRH) and somatostatin. Growth hormone circulates bound to a binding protein which represents a soluble receptor and it binds in most tissues to its own speci®c receptor. The anabolic actions of growth hormone are mediated by insulin-like growth factor-I (IGF-I) which is synthesized in most tissues, but the majority of circulating IGF-I is derived from the liver. IGF-I circulates bound to a number of different proteins and its biological actions are modulated by these binding proteins. In particular, IGF-I levels are stable over a 24 h period in health due to its binding in a complex with insulin-like growth factor binding protein-3 (IGFBP-3). In many illnesses, a protease appears which reduces the af®nity of IGFBP-3 for IGF-I and increases its clearance from the circulation. IGFBP-1 is a small molecular weight binding protein whose levels are acutely modulated by nutrition and have an inverse relationship with insulin levels. In most bioassays, IGFBP-1 is inhibitory but there is some suggestion that IGFBP-1 may act to carry IGF-I into the tissues.
Nutritional state has profound actions at all levels of the GHaIGF-I axis and growth hormone has potent effects on nutritional state. The growth promoting effects of GH on linear height in children has long been recognized and, more recently, the important actions of GH in maintaining normal adult body composition have been appreciated. The strong anabolic actions of GH have made it a drug of abuse among athletes and, of interest to the clinicians, as a potential anti-catabolic therapy. Other chapters from this symposium will discuss the effects of obesity on GH secretion and so in this chapter we have focused on the changes in the GHaIGF-I axis associated with fasting and catabolic illness (Figure 1 ).
Fasting
Fasting is always associated with a fall in IGF-I secretion and levels. 1 In the early experiments in the 1980s it was demonstrated that a fast over 4 days resulted in an impressive fall in IGF-I levels and that these only recovered fully when subjects were re-fed an isocaloric diet with appropriate protein supplementation. A diet without protein did not result in full restoration of IGF-I levels, demonstrating that not only calories were required but that protein was important for maintaining IGF-I levels. This fall in IGF-I levels is accompanied by a change in the GH pro®le. During a 5 day fast, there is an increase in overall growth hormone secretion seen at 24 h, which is further increased at 5 days. 2 Of importance, there is a change in the GH pro®le with an increase in interpulse or basal GH levels. 2 In a more detailed investigation, the pulse amplitude of GH secretion during fasting was demonstrated to be increased as well as the total and interpulse GH levels. 3 One of the earliest changes in the IGF-I axis is a rise in IGFBP-1 levels. BP-1 levels rise during overnight as insulin levels fall, and then as the fast is continued the BP-1 levels continue to rise. 4 Overall, the changes seen with fasting represent GH resistance with respect to the generation of IGF-I with high GH levels, low IGF-I levels and increased inhibitory binding protein levels of IGFBP-1. These changes in the GHaIGF-I axis are common to many different disease states. For this reason it is dif®cult to distinguish speci®c changes in the GHaIGF-I axis from those associated with fasting. In the next three sections we consider three states of hypercatabolism associated with changes in the GHaIGF-I axis.
Chronic liver disease
Chronic liver disease has always been considered as one of the classical forms of acquired GH resistance. These patients have severe protein calorie malnutrition, muscle wasting and the nutritional state is the most important predictor of their outcome. In cirrhosis, IGF-I and IGFBP-3 levels are low, and GH secretion is increased with both an increase in pulse amplitude and basal growth hormonal levels and there is an associated rise in IGFBP-1. 5, 6 The changes in the GHaIGF-I axis correlate with both markers of reduced liver cell function as well as markers of nutritional state. It has been assumed that the acquired GH resistance is due to an absence of GH receptor on the cirrhotic liver. 7 However, recently we have clearly demonstrated the presence of GH receptor on cirrhotic liver from patients with end stage liver failure undergoing transplantation. 8 In addition, cirrhotic liver remains transcriptionally active and is able to express all components of the GHaIGF-I axis. In particular, cirrhotic patients have high levels of IGFBP-l, which is thought to be predominantly derived from the liver. 9, 10 In view of the presence of the components of the GHaIGF-I axis in cirrhotic patients, we undertook a double-blind placebo controlled study of GH therapy in cirrhotic patients. Patients were treated for 7 days with GH at a supraphysiological dose (0.25 Uakgaday) for 7 days. GH treatment was associated with a doubling in IGF-I levels although the response was considerably less than that seen in normal subjects con®rming their GH resistance. The rise in IGF-I levels was accompanied by an improved in cumulative nitrogen balance. 11 However, of interest, the response to GH therapy was clearly nutritionally dependent, as illustrated by one patient (Figure 2 ). In this patient IGF-I levels were maintained during GH therapy until an intercurrent episode of vomiting when IGF-I levels dramatically fell.
Thus, it is likely that a component of the GH resistance seen in chronic liver disease is due to reduced nutritional intake and disturbance of the liver architecture rather than an absence of GH receptor on the cirrhotic liver. GH treatment can improve surrogate markers of nutritional state but the longterm effects of GH are not known.
Post-surgical patients
Post-surgical patients make an important group to study because we can more clearly de®ne the time of the catabolic insult. A detailed study of IGF and its binding protein was performed in 12 patients following abdominal surgery. 12 In these patients there was an acute fall of IGF-I at the time of surgery which then continued to fall, with a nadir at 4 days. IGF-I levels did not recover to the pre-surgical levels until 14 days following surgery and intriguingly, following this there was a rebound rise in IGF-I levels. IGFBP-3 levels showed an almost parallel change to IGF-I levels. In contrast, IGFBP-2 levels showed an inverse relationship to IGFBP-3 levels and IGFBP-1 had a distinct pattern with an acute rise in levels at the time of surgery followed by slightly high basal levels during the next 14 days. At the time of surgery, a protease appeared which reduced the af®nity of IGF-I for IGFBP-3. It is interesting to note that the changes in IGF-I levels very much parallel the increase in nitrogen excretion seen with trauma. 13 The change in Figure 1 Summary of changes in the GHaIGF-I axis according to nutritional state. Figure 2 Changes in IGF-I and nitrogen balance in a patient with end stage liver failure treated with GH. Vomiting was associated with a fall in IGF-I levels despite GH therapy.
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Growth hormone and nutrition RJM Ross IGF-I levels almost certainly re¯ects an increase in clearance as demonstrated by studies administering IGF-I to post-surgical patients. 14 
Critical illness and sepsis
Critical illness and sepsis probably represent the most dif®cult patient groups to study. These patients form a very heterogeneous group with the etiology ranging from respiratory failure due to pneumonia to intradominal sepsis following abdominal surgery for aortic aneurism. In addition, although the initial insult may result in multi-organ failure, the recovery phase of illness may often be accompanied by other infections causing acute illness during a chronic phase. This group represents one of the more important groups to study as they also have the most severe nutritional disturbance and may well bene®t from an intervention which would improve their nutritional state. In a recent review the changes in anterior pituitary hormones were considered with respect to the stage of critical illness. 15 In this summary, it was suggested that the acute phase of illness was associated with a rise in anterior pituitary hormones followed by a chronic phase, when anterior pituitary hormone levels fell, and then a recovery phase when they rose again. The change in anterior pituitary hormones is generally associated with low peripheral target hormones except for cortisol, whose levels are high. For growth hormone secretion a consistent ®nding in most publications has been a reduction in pulsatile GH secretion with a rise in interpulse GH levels. 16 ± 18 Overall, GH secretion has variously been reported as high, normal or low. IGF-I levels, however, are consistently low and parallel changes in the nutritional state. 19 IGF-I levels also rise in survivors, but remain low in non-survivors and most critically ill patients on the intensive care unit have protease activity reducing the af®nity of IGF-I or BP-3. 20, 21 The half life of administered IGF-I is also low and probably re¯ects the presence of protease activity. 22 
GH as an anabolic therapy in catabolic illness
It is not within the remit of this chapter to discuss GH as an anabolic therapy in catabolic illness. However, the recent preliminary results from the intensive care unit make it important to mention this topic. There are over 60 publications in the literature using pharmacological doses of GH as an anabolic therapy in various catabolic states which vary from the postsurgical patient to critical illness to the burns patient. 23 Because of the association between acquired GH resistance and protein hypercatabolism and the many studies suggesting an improvement in nutritional state with GH therapy, a large multi-centre study was started within Europe looking at GH administration to Intensive Care Unit patients. In a carefully controlled blinded randomized study of patients with an expected long stay on ICU, GH therapy was associated with a doubling of mortality (personal communication). The explanation for this result remains unknown. However, there are some suggestions from the animal literature suggesting that GH therapy may interact with endotoxin and produce a poor outcome. 24, 25 At present, the role of GH as an anticatabolic agent remains to be de®ned.
